AAIC 2025 Abstract
Frequent at‐home multimodal measurements are more sensitive to progression than the gold‐standard clinic‐based ADAS‐Cog composite scale
By Laura M. Rueda-Delgado, Florentine Marie Barbey, Alison R. Buick, Show 4 more authorsBrian Murphy
Study in peopleBiomarkers
Abstract
Background: The detection of progression is key to the statistical power of placebo‐controlled clinical trials. This is a challenge in dementia, as disease progression is confounded with natural aging, and as widely used assessments (CDR, ADAS‐Cog) lack sensitivity and are administered only infrequently and in specialist settings.
